Literature DB >> 8000729

Costs and benefits of outpatient therapy.

E B Rubenstein1.   

Abstract

In recent years, much of the care traditionally rendered in hospitals has been shifted to ambulatory settings. This change has been fueled as much by changing patterns of reimbursement as by rapid developments in medicine and technology. The current climate of health-care reform suggests that this trend will continue for the near future. Unfortunately, there are few studies that systematically evaluate the cost effectiveness or benefits of ambulatory care. Among the few such studies published to date, the results are not overwhelmingly positive. While the monetary costs of ambulatory care are generally far lower than inpatient management, several studies suggest that family and household disruption are prominent features of outpatient strategies. Thus, the measurement of the direct and indirect costs and benefits of ambulatory treatment presents a significant challenge to researchers. Development of methodologies to support such studies must be among our highest priorities.

Entities:  

Mesh:

Year:  1994        PMID: 8000729     DOI: 10.1007/BF00365584

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  11 in total

1.  Rhode Island patients undergoing outpatient chemotherapy.

Authors:  V Mor; S Masterson-Allen
Journal:  R I Med J       Date:  1990-10

2.  A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.

Authors:  E E Vokes; R L Schilsky; K E Choi; D M Magid; C M Guarnieri; S M Whaling; M J Ratain; R R Weichselbaum; W R Panje
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

3.  Oncology: who's managing outpatient programs?

Authors:  K Sandrik
Journal:  Hospitals       Date:  1990-02-05

4.  Outpatient cisplatin chemotherapy in a community hospital cancer center.

Authors:  J A Young; S Segler
Journal:  J Okla State Med Assoc       Date:  1985-09

5.  The human costs of cancer and the response of the National Cancer Program.

Authors:  S Broder
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

Review 6.  Changing cancer care in the 1990s and the cost.

Authors:  J W Yarbro
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

7.  Free-standing cancer centers: rationale for improving cancer care delivery.

Authors:  J J Lokich; S Silvers; H Brereton; J Byfield; R Bick
Journal:  Am J Clin Oncol       Date:  1989-10       Impact factor: 2.339

8.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

9.  Re-evaluating the cost of outpatient cancer chemotherapy.

Authors:  H B Wodinsky; C DeAngelis; J J Rusthoven; I G Kerr; D Sutherland; N Iscoe; R Buckman; M Kornijenko
Journal:  CMAJ       Date:  1987-11-15       Impact factor: 8.262

10.  Cancer at the crossroads.

Authors:  K Lumsdon; H J Anderson
Journal:  Hospitals       Date:  1992-12-05
View more
  6 in total

1.  Children's cancer pain in a world of the opioid epidemic: Challenges and opportunities.

Authors:  Michelle A Fortier; Sun Yang; Michael T Phan; Daniel M Tomaszewski; Brooke N Jenkins; Zeev N Kain
Journal:  Pediatr Blood Cancer       Date:  2019-12-18       Impact factor: 3.167

2.  Antiemetic treatment for cancer chemotherapy: problems and progress.

Authors:  R J Gralla
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

3.  Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.

Authors:  Ami Vyas; S Suresh Madhavan; Usha Sambamoorthi; Xiaoyun Lucy Pan; Michael Regier; Hannah Hazard; Sita Kalidindi
Journal:  J Natl Compr Canc Netw       Date:  2017-11       Impact factor: 11.908

4.  Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.

Authors:  Vito Lorusso; Marianna Giampaglia; Luciana Petrucelli; Valeria Saracino; Tania Perrone; Antonio Gnoni
Journal:  Support Care Cancer       Date:  2012-04-26       Impact factor: 3.603

5.  Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

Authors:  F Longo; G Mansueto; V Lapadula; L Stumbo; G Del Bene; D Adua; L De Filippis; E Bonizzoni; S Quadrini
Journal:  Int J Clin Pract       Date:  2012-07-02       Impact factor: 2.503

6.  To reduce the average length of stay of patients who are admitted for DA-EPOCH-R chemotherapy regimen.

Authors:  Yee Mei Lee
Journal:  BMJ Qual Improv Rep       Date:  2015-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.